Fourth Quarter & Full Year 2022 Financial & Business Update
Forward-Looking Statements
Certain of the statements made in this presentation are forward looking, such as those, among others, relating to the Company's 2023 outlook,
including anticipated product sales, revenues, costs and expenses, and its potential for growth; the Company's potential to achieve the noted
development and regulatory milestones in 2023 and in future periods, or at all; anticipated activities related to the Company's planned and ongoing
clinical trials; the opportunities for, and the therapeutic and commercial potential of, ADCETRIS, PADCEV, TUKYSA, TIVDAK, disitamab vedotin,
ladiratuzumab vedotin, the Company's other product candidates, its technologies, and the products and product candidates of its licensees and
collaborators; the potential for PADCEV to receive accelerated approval from the FDA based on data from the EV-103 trial; the potential for the
Company's products and product candidates to receive regulatory approvals or label expansions; the Company's pipeline; as well as other statements
that are not historical fact. Actual results or developments may differ materially from those projected or implied in these forward-looking statements.
Factors that may cause such a difference include without limitation: the risks that the Company's ADCETRIS, PADCEV, TUKYSA and TIVDAK net
sales, revenues, expenses, costs and financial guidance may not be as expected; risks and uncertainties associated with maintaining or increasing
sales of ADCETRIS, PADCEV, TUKYSA and TIVDAK due to competition, unexpected adverse events, regulatory action, pricing and/or reimbursement
actions, market adoption by physicians, drug pricing reform, impacts associated with COVID-19 or other factors; the risks that the Company or its
collaborators may be delayed or unsuccessful in planned clinical trial initiations, enrollment in and conduct of clinical trials, obtaining data from clinical
trials, planned regulatory submissions, and regulatory approvals in the U.S. and in other countries, in each case for a variety of reasons including
without limitation the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected
adverse events or regulatory actions and the inherent uncertainty associated with the regulatory approval process; risks relating to collaborations; risks
related to the COVID-19 pandemic, the ongoing military conflict between Russian and Ukraine, related sanctions, and related economic, financial and
other disruptions. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" included in
the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and the Company's subsequent periodic reports filed with
the SEC. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise except as required by applicable law.
Seagen
2View entire presentation